Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 161,568
  • Shares Outstanding, K 13,464
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,380 K
  • 60-Month Beta 1.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.96
Trade ENLV with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.27 +45.10%
on 12/31/20
12.10 -0.83%
on 01/20/21
+1.11 (+10.19%)
since 12/18/20
3-Month
7.92 +51.44%
on 11/17/20
14.00 -14.29%
on 10/21/20
-1.80 (-13.04%)
since 10/20/20
52-Week
3.59 +234.26%
on 03/18/20
16.94 -29.16%
on 02/24/20
+3.07 (+34.41%)
since 01/17/20

Most Recent Stories

More News
Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the H.C. Wainwright BioConnect...

ENLV : 12.00 (+10.19%)
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv

- Comparison of 10 Allocetra-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile and extremely...

ENLV : 12.00 (+10.19%)
Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News

Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.

BCRX : 9.24 (+1.93%)
AMGN : 252.36 (+1.65%)
VRTX : 236.70 (+2.07%)
CRIS : 11.55 (-6.40%)
FATE : 109.01 (-4.64%)
CRSP : 189.77 (-4.30%)
ENLV : 12.00 (+10.19%)
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a new patent...

ENLV : 12.00 (+10.19%)
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today reported positive interim results of an investigator-initiated Phase II clinical trial evaluating...

ENLV : 12.00 (+10.19%)
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options *

ENLV : 12.00 (+10.19%)
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company's Board of Directors

* Dr. Schwartz Served as ArQule's Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 *

ARQL : 20.00 (+0.15%)
ENLV : 12.00 (+10.19%)
MRK : 82.46 (-0.88%)
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright's 6th Annual Israel Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today announced that it will present the clinical development schedule for its Sepsis, COVID-19 and Solid...

ENLV : 12.00 (+10.19%)
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, and Ulcerative Colitis with Allocetra Immunotherapy

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent...

ENLV : 12.00 (+10.19%)
What's in the Cards for Enlivex (ENLV) This Earnings Season?

Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.

MYL : 15.85 (+1.96%)
GERN : 1.7400 (-1.69%)
RGNX : 44.63 (-6.73%)
ENLV : 12.00 (+10.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

3rd Resistance Point 13.93
2nd Resistance Point 13.01
1st Resistance Point 12.51
Last Price 12.00
1st Support Level 11.09
2nd Support Level 10.17
3rd Support Level 9.67

See More

52-Week High 16.94
Last Price 12.00
Fibonacci 61.8% 11.84
Fibonacci 50% 10.27
Fibonacci 38.2% 8.69
52-Week Low 3.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar